Molecular markers of prognosis in astrocytic tumors

Cancer

Volumn 94, Issue 10, 2002, Pages 2688-2697

  Rasheed, Ahmed ^a   Herndon, James E ^a   Stenzel, Timothy T ^a   Raetz, Jacqueline G M ^a   Kendelhardt, Jason ^a   Friedman, Henry S ^a   Friedman, Allan H ^a   Bigner, Darell D ^a   Bigner, Sandra H ^a   McLendon, Roger E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astrocytoma; CDKN2A; PTEN; Glioma; TP53; Tumor suppressor gene

Indexed keywords

MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53;

AGE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER SURVIVAL; CHILD; CHROMOSOME 16P; CHROMOSOME 9P; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GENES, SUPPRESSOR; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 0037093971     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10544     Document Type: Article

References (55)

1. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice
2. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
3. Comprehensive allelotype and genetic analysis of 466 human nervous system tumors
4. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
5. Glioma classification - A molecular reappraisal
6. Specific chromosomal abnormalities in malignant human gliomas
7. Clonal genomic alterations in glioma malignancy stages
8. Mitotic recombination of chromosome 17 in astrocytomas
9. Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons
10. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas
11. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
12. A cell cycle regulator potentially involved in genesis of many tumor types
13. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
14. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
15. Mutations in the p53 gene occur in diverse human tumour types
16. p53, the cellular gatekeeper for growth and division
17. Rb function in cell-cycle regulation and apoptosis
18. PTEN: Life as a tumor suppressor
19. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays
20. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme
21. p53 status has no prognostic significance in glioblastomas treated with radiotherapy
22. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas
23. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers
24. Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation
25. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
26. MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
27. Long-term survival of glioblastoma multiforme: Importance of histopathological reevaluation
28. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme
29. Genetic sub-types of human malignant astrocytoma correlate with survival
30. Long-term survivors of glioblastoma multiforme: Clinical and molecular characteristics
31. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival
32. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study
33. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients
34. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes
35. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas
36. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value
37. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas
38. Alterations of the TP53 gene in human gliomas
39. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25
40. PTEN gene mutations are seen in high-grade but not in low-grade gliomas
41. Microsatellite analysis of childhood brain tumors
42. Deletion of p16 and p15 genes in brain tumors
43. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
44. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas
45. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas
46. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
47. Genetic alterations during colorectal-tumor development
48. Subsets of glioblastoma multiforme defined by molecular genetic analysis
49. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
50. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
51. The glioblastoma multiforme in Georgia, 1977-1981
52. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas
53. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor